Genmab upgrades financial guidance again

Darzalex sales are going so well that Genmab has increased its top and bottom line expectations. It also now expects lower costs than previously estimated.

Photo: Joost Melis / Genmab / PR

Sales of Darzalex, which is a bone marrow cancer drug, are significantly exceeding expectations, Genmab reports in a stock exchange notification.

The company has therefore decided to upgrade its financial guidance for the full year to an operating result of DKK 2.3-3.2bn (USD 360-500m) and a revenue of DKK 7.9-8.5bn (USD 1.2-1.3bn). Previously, Genmab had expected an operating result of DKK 1.5-2.4bn (USD 230-370m) and a revenue of DKK 7.3-7.9bn (USD 1.1-1.2bn).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs